Kaneka Completes Construction of Medical Device Plant in Hokkaido
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido for the purpose of portfolio transformation and business expansion and held the opening ceremony on August 26. The Tomatoh Manufacturing Site is the seventh domestic business location*1 for the company and the first new one in 54 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829240050/en/
Tomatoh Manufacturing Site (Photo: Business Wire)
The medical device plant*2 completed at Tomatoh Manufacturing Site will produce adsorption type blood purification devices "Rheocarna™" and adsorption type plasma purification devices "Liposorber™". The number of patients with arteriosclerosis obliterans (ASO)*3, which these medical devices are intended to treat, is on the rise worldwide, along with increases in diabetes, chronic renal failure, and other conditions. By securing the supply base through the new plant, we will dramatically expand our medical business to meet global demand.
The plant has achieved full automation of its production lines as a "smart factory" utilizing robot technology and plans to realize a "zero energy factory" that will reduce the primary energy consumption of the factory building to zero by using our photovoltaic modules, thereby promoting sustainable manufacturing.
In the future, Tomatoh Manufacturing Site will be actively utilized as a new production base for each business, as well as for further expansion of the medical business.
Based on our mission of "KANEKA thinks 'Wellness First'.", we will realize a world where advanced medical care is accessible to everyone and where science contributes to the innovation of the global environment and our daily lives. From Tomakomai, "Kaneka, the Dream Factory" will make this vision a reality.
Participants at the opening ceremony (From the left):
Yoshiro Aikawa, President of Taisei Corporation
Jun Kimura, Deputy Mayor of Tomakomai-city
Naomichi Suzuki, Governor of Hokkaido
Kimikazu Sugawara, Chairman of Kaneka Corporation
Kazuhiko Fujii, President of Kaneka Corporation
Shigenobu Sano, Senior Executive Director of Tomatoh Co., Ltd.
*1. Domestic business locations: Takasago Manufacturing Site, Osaka Manufacturing Site, Shiga Manufacturing Site, Kashima Manufacturing Site, Tomatoh Manufacturing Site, Tokyo Head Office, Osaka Head Office
*2. News Release January 23, 2022
Kaneka to Construct New Medical Device Plant in Hokkaido - Roughly 10 billion yen investment aimed at expanding global business -
https://www.kaneka.co.jp/en/topics/news/2022/ennr2201241.html
*3. A disease that causes arteriosclerosis where stenosis and occlusion of lower limbs artery occurred, leading to impaired blood flow (ischemia). In the early stages, it causes coldness, numbness, and gait disturbance. When the disease progresses to critical limb ischemia with pain and ulceration, the risk of leg amputation and death increases.
About Tomatoh Manufacturing Site
Company Name: Kaneka Corporation Tomatoh Manufacturing Site
Completed: August 26, 2024
Location: 6-253 Kashiwabara, Tomakomai-city, Hokkaido
Business Description: Production of medical devices
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829240050/en/
Contacts
KANEKA CORPORATION
Investors & Public Relations Department
Chika Harada
Info_Pro@kaneka.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dr. Wolff Group Working with Kinaxis and mSE Solutions to Bring Supply Chain Clarity to Personal Care Product Portfolio10.9.2024 14:52:00 EEST | Press release
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Dr. Wolff Group, a family-owned German manufacturer of cosmetic and pharmaceutical products, is working with Kinaxis, along with mSE Solutions, an expert supply chain optimization consultancy, to help drive faster and more accurate decision-making in supply chain planning and thus ensure a better balance between market and supply chain dynamics. A growing company that exports its popular brands including Alpecin, Alcina, and Plantur among others, to more than 60 countries worldwide, Dr. Wolff faced challenges in managing its complex and diverse product portfolio that includes everything from hair care and styling products, to decorative cosmetics, dental care, and vaginal and dermatologic pharmaceuticals. In order to be able to react even more flexibly, quickly and efficiently to customer requirements, the company turned to mSE Solutions and Kinaxis to strengthen its supply chain pr
Total Economic Impact Study Reveals a Return on Investment of 184% for Veracode Application Risk Management Platform Customers10.9.2024 14:50:00 EEST | Press release
Veracode, a global leader in application risk management, today released a commissioned study conducted by Forrester Consulting on The Total Economic Impact™ (TEI) of Veracode’s Application Risk Management Platform. The study revealed that Veracode delivered a 184 percent return on investment (ROI) to customers over a three-year period, as well as a material Net Present Value and a payback period of less than six months. Specifically, there were four key drivers of the economic impact: A 75 percent reduction in risk of software-based attacks 80 percent developer productivity recapture that can be reallocated to product innovation 85 percent efficiency gained in application security from increased automation Most noteworthy, a 20 percent growth in revenues from software security that drove new products, new market entries, speed to market, and security as a differentiator With software supply chain attacks on the rise, security and DevSecOps leaders need ways to source solutions that de
Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients10.9.2024 14:00:00 EEST | Press release
Following to the previous information on April 8th. 2024, we are excited to share our latest development status. A Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) who had one prior treatment with VEN involved regimen was approved by the US Food and Drug Administration (FDA) on April 8 this year (Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax | Business Wire). Subsequently, we are pleased to announce that the first patient was enrolled at the University of Virginia Hospital based on the approval of the Investigational Review Board (IRB). The University of Virginia Hospital is the clinical site that enrolled the most patients to the Phase III study of DFP-10917 monotherapy in patients with failed/relapsed AML. Some pharmaceutical companies have already expressed interest in the Phase III study of DFP-10917 monotherapy. Additionally, many companie
SLB achieves breakthrough results in sustainable lithium production10.9.2024 13:56:00 EEST | Press release
SLB today announced it has proven its solution for sustainable lithium production at scale at its demonstration plant in Clayton Valley, Nevada, to accelerate responsibly-sourced lithium products to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909767336/en/ SLB's demonstration plant in Clayton Valley proves its unique integrated approach to produce scalable quantities of lithium in the fastest, most economical and sustainable way for today’s market. (Photo: Business Wire) The proprietary integrated solution combines SLB’s subsurface expertise with surface engineering of advanced technologies that include direct lithium extraction (DLE). It produces lithium 500 times faster than conventional methods while using only 10 percent of the land. Operating at approximately one tenth the size of a commercial-scale facility, the plant reached a verified recovery rate1 of 96% lithium from brine. SLB’s integrated solution i
Eaton to Showcase Technologies for Hydrogen-Powered Commercial Vehicles at IAA Transportation 202410.9.2024 13:30:00 EEST | Press release
Intelligent power management company Eaton announced it will showcase a broad range of innovative solutions for hydrogen-powered commercial vehicles September 17–22 at IAA Transportation 2024 in Hanover, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910157651/en/ Eaton’s hydrogen recirculation blower cycles surplus hydrogen to the stack's inlet, which extends system longevity through anode purging. (Photo: Business Wire) “Eaton believes that hydrogen can play a significant role in decarbonizing commercial vehicles,” said Scott Adams, senior vice president, Global Products, Eaton’s Mobility Group. “Whether a vehicle is powered by hydrogen fuel cells or a hydrogen internal combustion engine, Eaton’s broad range of innovative solutions makes us a valuable supplier partner.” Eaton’s TVS technology improves fuel cell performance Recirculating excess hydrogen through the fuel cell stack is critical for achieving high
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom